Form 4: Stoke Therapeutics Director Arthur Levin Granted Significant Stock Options

Stoke Therapeutics, Inc. Director Arthur A. Levin was granted 29,747 stock options with an exercise price of $10.90, aligning his interests with long-term shareholder value.

Summary

• Arthur A. Levin, a Director at Stoke Therapeutics, Inc. (STOK), was granted 29,747 stock options.
• The options have an exercise price of $10.90 per share.
• The transaction date for this grant was June 3, 2025.
• The options will vest in full on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, contingent on Mr. Levin's continued service to the issuer.
• The options are exercisable until June 2, 2035.
• Following this transaction, Mr. Levin beneficially owns 29,747 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and confidence in future performance. It's a standard compensation practice that incentivizes long-term value creation, though it doesn't reflect immediate financial performance.

Positives

• The grant of stock options to Director Arthur A. Levin aligns his personal financial interests with the long-term performance and shareholder value creation of Stoke Therapeutics.
• The options have a 10-year expiration period (until June 2, 2035), providing a long-term incentive for the director.
• The vesting schedule, tied to continued service, encourages retention of key board members.

Risks

• The value of the stock options is dependent on the future stock price performance of Stoke Therapeutics, Inc. If the stock price does not exceed the exercise price of $10.90, the options may expire worthless.
• The vesting of the options is subject to the director's continued service, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

This filing does not provide a general future outlook for the company but indicates a long-term incentive for a director, suggesting a focus on future value creation.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Stoke Therapeutics, to incentivize long-term performance and align management interests with shareholder returns. This practice is standard for attracting and retaining experienced board members in a competitive sector.

Comparison to Industry Standards

• The grant of 29,747 stock options to a director with a 10-year term and service-based vesting is consistent with typical compensation practices for board members in publicly traded biotechnology companies.
• While specific comparable companies (e.g., Sarepta Therapeutics, Alnylam Pharmaceuticals, Ionis Pharmaceuticals) would have varying grant sizes based on company stage, market capitalization, and individual director roles, the structure of this option grant aligns with industry norms for incentivizing long-term value creation and retaining experienced leadership.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing stock value.

Next Steps

• The options will vest on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, subject to continued service.
• The director may exercise the options at any time after vesting and before the expiration date of June 2, 2035.

Key Dates

Recommendation

Keywords

Stoke Therapeutics, STOK, Form 4, SEC Filing, Insider Trading, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant, Corporate Governance